2241664-16-2

Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD₅₀) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved^[1].
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD₉₀), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival^[1].